Our data suggest that Swiss physicians prefer FTD/TPI followed by regorafenib as the optimal treatment sequence in patients with comorbidities and previous tolerability issues, regardless of KRAS mutation status. This evidence concerns the gene KRAS and frontotemporal dementia.